IRIS
RADAELLI, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.788
NA - Nord America 1.116
EU - Europa 1.045
SA - Sud America 491
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.471
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.067
SG - Singapore 816
CN - Cina 489
BR - Brasile 430
SE - Svezia 305
RO - Romania 264
HK - Hong Kong 215
VN - Vietnam 128
IT - Italia 106
DE - Germania 100
RU - Federazione Russa 72
GB - Regno Unito 48
FI - Finlandia 34
IN - India 28
AR - Argentina 24
NL - Olanda 24
CA - Canada 21
JP - Giappone 21
MX - Messico 19
PL - Polonia 18
ZA - Sudafrica 18
IR - Iran 17
TR - Turchia 17
BD - Bangladesh 15
EC - Ecuador 15
IE - Irlanda 15
FR - Francia 14
ID - Indonesia 14
ES - Italia 10
AT - Austria 9
CO - Colombia 6
CH - Svizzera 5
CL - Cile 5
PY - Paraguay 5
SA - Arabia Saudita 5
UA - Ucraina 5
IQ - Iraq 4
JO - Giordania 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
EG - Egitto 3
PE - Perù 3
AL - Albania 2
DO - Repubblica Dominicana 2
EU - Europa 2
HU - Ungheria 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
PA - Panama 2
PK - Pakistan 2
PT - Portogallo 2
TN - Tunisia 2
UY - Uruguay 2
BB - Barbados 1
BE - Belgio 1
CI - Costa d'Avorio 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 4.471
Salva come PNG Salva come JPEG
Città #
Singapore 336
Dallas 291
Hong Kong 213
Ashburn 113
Hefei 103
Shanghai 102
Beijing 79
Lawrence 72
Princeton 72
Munich 64
Ho Chi Minh City 53
New York 45
Los Angeles 43
Milan 38
São Paulo 38
Boardman 34
Moscow 30
Hanoi 24
Helsinki 16
Dublin 15
Warsaw 15
Rio de Janeiro 14
Tokyo 14
Turku 14
Denver 12
Manchester 12
Rome 12
Ankara 11
Chennai 11
Johannesburg 11
Orem 11
Brooklyn 10
Montreal 10
Nuremberg 10
The Dalles 10
Brasília 9
Guangzhou 9
Mexico City 9
Amsterdam 8
Chicago 8
Dronten 8
Seattle 8
Tehran 8
Tianjin 8
Vienna 8
Da Nang 7
Haiphong 7
Houston 7
London 7
Phoenix 7
Poplar 7
Stockholm 7
Mumbai 6
Pune 6
Ribeirão Preto 6
Washington 6
Bergamo 5
Campinas 5
Duque de Caxias 5
Osasco 5
Quito 5
Zurich 5
Amman 4
Aracaju 4
Atlanta 4
Belo Horizonte 4
Cesano Boscone 4
Changsha 4
City of London 4
Cotia 4
Frankfurt am Main 4
Goiânia 4
Guarulhos 4
Hangzhou 4
Izmir 4
Lappeenranta 4
Medellín 4
Porto Alegre 4
Querétaro 4
Salvador 4
San Francisco 4
Santa Fe 4
Secaucus 4
Tashkent 4
Toronto 4
Araçatuba 3
Belford Roxo 3
Campina Grande 3
Campo Grande 3
Cerquilho 3
Curitiba 3
Dhaka 3
Feira de Santana 3
Fortaleza 3
Gronau 3
Guarapuava 3
Guayaquil 3
Ikejiri 3
Itajaí 3
Jackson 3
Totale 2.281
Salva come PNG Salva come JPEG
Nome #
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study 315
Application of Deep-Learning to NMOSD and Seronegative Patients with Limited NMOSD Manifestations 139
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study 102
Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. 77
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography 74
Autologous haematopoietic stem cell transplantation with thiotepa-cyclophosphamide conditioning in aggressive multiple sclerosis: clinical experience in eight patients 70
U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene 66
the multiple sclerosis knowledge Questionnaire: a self administered instrument of recently diagnosed patients 65
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 65
Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica 64
Allogeneic haematopoietic stem cell transplantation in refractory neuromyelitis optica spectrum disorders 64
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod 64
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response 63
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 60
Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis 60
Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients 58
Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders 57
In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis 56
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 55
Dysregulation of MS risk genes and pathways at distinct stages of disease 54
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) 54
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis 53
Autologous haematopoietic stem cell transplantation in aggressive forms of neuromyelitis optica (NMO) and NMO spectrum disorders 51
Critical role for prokineticin 2 in CNS autoimmunity 50
Brain and cord imaging features in neuromyelitis optica spectrum disorders 50
Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72 49
Breastfeeding is not related to postpartum relapses in multiple sclerosis 48
Forceps minor damage and co-occurence of depression and fatigue in multiple sclerosis 48
Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach 48
Clinical and MRI predictors of response to interferon‐beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients 47
Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis 46
Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation in aggressive forms of multiple sclerosis: results in 9 patients 45
Experience of an information aid for newly diagnosed multiple sclerosis patients: A qualitative study on the SIMS-Trial 45
THIOTEPA-CYCLOPHOSPHAMIDE HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE FORMS OF MULTIPLE SCLEROSIS: RESULTS IN 9 PATIENTS 44
Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice 44
Evolving concepts in the treatment of relapsing multiple sclerosis 43
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 42
Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder 41
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. 41
Are Recurrent Myelitis a Prodromic Phase of Inflammatory Diseases or a Distinct Inflammatory Condition? 40
Application of deep-learning to NMOSD and unclassified seronegative patients 40
Natalizumab treatment after autologous haematopoietic stem cell transplantation in patients with aggressive multiple sclerosis 40
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. 39
Efficacy and safety of nabiximols (Sativex (R)) on multiple sclerosis spasticity in a real-life Italian monocentric study 39
Optical coherence tomography and visual-evoked potentials: which is more sensitive in multiple sclerosis? 39
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study 39
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. 39
Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients 39
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 39
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 38
Mapping regional grey and white matter atrophy in relapsing-remitting multiple sclerosis. 38
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis 38
Use of brain MRI and gene expression atlases to reconstruct the pathophysiology of autoimmune neurological disorders: The proof-of-concept of NMOSD 37
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment 37
Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients 36
Evoked potentials scores: a useful tool in monitoring and predicting the course of multiple sclerosis? 36
Evoked Potential Abnormalities Predict Disability Progression at 5 Years in Patients with CIS 36
Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood 36
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes 36
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study 36
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. 36
Signs and symptoms of COVID-19 in patients with multiple sclerosis 35
Mitoxantrone: benefits and risks in multiple sclerosis patients 35
Evoked potential abnormalities predict disability progression at 5 years in patients with CIS 35
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. 35
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results 35
Sars-CoV2 infection in pregnant women with multiple sclerosis 34
White Matter Myelin Alterations are Diffuse in Neuromyelitis Optica Spectrum Disorders and Prevail on Axonal Damage 34
Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: a case report 34
MGAT5 and disease severity in progressive multiple sclerosis 34
Disclosing the diagnosis of multiple sclerosis: The Profile Project 34
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. 33
Regional gray matter atrophy is largely unrelated to white matter tissue loss in relapsing remitting multiple sclerosis. 33
Neuromyelitis optica: Concepts in evolution 33
Artificial Intelligence on Conventional Magnetic Resonance Images for the Diagnosis of Neuromyelitis Optica Spectrum Disorders 33
Neuromyelitis optica remission after allo-SCT: results in 2 patients and correlation with T- and B-cell biomarkers of tolerance 32
Oral corticosteroids for multiple sclerosis relapse 32
Recurrence of disease activity after repeated Natalizumab withdrawals. 30
NMO spectrum disorder and optic neuritis: are VEPs useful? 30
Differential diagnosis of optic neuritis in neuromyelites optica and multiple sclerosis: are VEPs useful? 30
Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. 30
Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression 30
Brain and Spinal Cord Imaging Features in Neuromyelitis Optica Spectrum Disorders 30
Multiple sclerosis progression is not associated with birth timing in Italy 29
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study 29
Spinal cord atrophy in neuromyelitis optica is spatially associated to spinal cord lesions and clinical disability 29
White matter myelin alterations are diffuse in Neuromyelitis Optica spectrum disorders and prevail on axonal damage 29
Practice of yoga may cause damage of bothsciaticnerves: a case report 27
Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis 26
Hippocampal Regional Vulnerability to Damage Differs Between MS and Neuromyelitis Optica 26
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 25
Hippocampal regional vulnerability to damage differs between MS and neuromyelitis optica 25
Revealing structural and clinical heterogeneity in the spectrum of neuromyelitis optica with unsupervised machine learning 24
Global and regional hippocampal volumes are preserved in neuromyelitis optica spectrum disorders and do not seem to be related to cognitive impairment 24
Global and regional hippocampal volumes are preserved in neuromyelitis optica spectrum disorders and do not contribute to cognitive impairment 24
Revealing structural and clinical heterogeneity in the spectrum of neuromyelitis optica with unsupervised machine learning 24
Golbal and Regional Hippocampal Volumes Are Preserved In Neuromyelitis Optica and Do not Seem to Be Related to Cognitive Impairment 23
White matter myelin alterations are diffuse in Neuromyelitis Optica Spectrum Disorders and prevail on axonal damage 22
Spinal cord atrophy in neuromyelitis optica spectrum disorders is associated to spinal cord lesions and clinical disability 22
Mr t2-relaxation time as an indirect measure of brain water accumulation in neuromyelitis optica spectrum disorders 20
Totale 4.499
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 2 2 0 3 0 1 0
2021/202244 0 0 0 30 1 2 1 3 2 3 0 2
2022/2023504 182 129 55 2 5 60 19 15 19 6 9 3
2023/2024229 7 26 22 26 27 42 4 20 0 7 10 38
2024/20251.593 130 14 20 59 69 85 434 102 262 131 121 166
2025/20262.143 339 376 378 679 350 21 0 0 0 0 0 0
Totale 4.567